Point of Care Testing for Pharmacy Technicians
Point of Care Testing for Pharmacy Technicians
Now more than ever, pharmacies are considered a place for front-line delivery of healthcare. This 4-hour training will equip you with the necessary skills to administer point of care tests in the pharmacy. Don’t miss the opportunity to assist pharmacists with testing services for your pharmacy’s patients.
Be prepared by taking this course that includes:
- Compliance requirements, including how to obtain a CLIA waiver
- Procedures for PPE, specimen collecting, and devices to use
- How to conduct tests for diabetes and hyperlipidemia
- How to administer tests for COVID-19, Influenza, HIV, Hepatitis C, and Group A Strep
- Documentation of hands-on specimen collection technique, specific to your pharmacy’s operations
Upon completion of the full course, pharmacy technicians should be able to:
1. Describe current trends in pharmacy practice and point of care testing (POCT)
2. List the pros/cons of implementing point of care testing
3. Identify the role pharmacists and pharmacy technicians can play in providing point of care testing services
4. Describe the process to obtain a clinical laboratory improvement amendment (CLIA) waiver license
5. List appropriate follow-up actions needed after conducting point of care testing (both internal and external)
6. Review the Centers for Disease Control and Prevention Self-Assessment Checklist for Good Testing Practice
7. Find CLIA resources and locate forms to assist in standardizing the point of care testing process
8. Review personal protective equipment (PPE) requirements for various POCTs
9. Compare and contrast the devices needed to administer an appropriate POCT
10. Collect specimen for diagnostic testing through nasal, throat, or blood routes
11. Describe patient characteristics for an individual at risk for diabetes and/or hyperlipidemia or who might benefit from a wellness screening
12. Describe patient characteristics for an individual at risk for infectious disease, including HIV, Hepatitis C, Group A Streptococcus, Influenza, and COVID-19
Faculty:
Brett Barker, PharmD
Anthony J. Bolus, PharmD, RPh
Julie Breuer, PharmD Candidate, University of Iowa
Patrick Devereux, PharmD, RPh
Alex Evans, PharmD, MBA
Michele Fountain, PharmD
John A Galdo, PharmD, MBA, BCPS, BCGP
David Hachey, PharmD, AAHIVP
Joshua David Kinsey, PharmD
Monica Nikseresht, Drake University
Alexis Page, PharmD
Kathryn Schott, PhD
Elizabeth Skoy, PharmD, RPh
John Galdo reports that he is CEO of Seguridad and his spouse works for Eli Lilly and was an employee of Prime Therapeutics. Brett Barker reports that he is an employee of Nucara. All relevant financial relationships have been mitigated.
The remaining faculty have no relevant financial relationships with ineligible companies to disclose.
This course was partially funded by an unrestricted educational grant from Roche Diagnostics Corporation.
Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: June 12, 2024
Planned Expiration Date: June 12, 2025
U/RN-4.24
CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.
¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.
Additional information
Duration | 4h 0m |
---|---|
Topic Designator | Disease State/Drug Therapy |
ACPE | Yes |
ACPE Topic | 04 Pharmacy Administration |
Role | Technician |
Media-Type | On-Demand |
Release Date | 6/12/24 |
CEUs | 0.4 |
ACPE Number | 0107-0000-24-187-H04-T |
This course is in our subscription.
Related products
-
2023 Diabetes Guideline Update: It’s a Whole New World
In Courses, PharmacistRated 0 out of 5$24.00 -
A Non-irritable Review of Irritable Bowel Syndrome (IBS) Guidelines
In Courses, PharmacistRated 0 out of 5$24.00 -
Annual Pharmacy Law Update: How COVID Exposed Legal Dilemmas in Patient Care
Rated 0 out of 5$34.00